CRISPR Therapeutics CRSP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$568.53M+2.2% | -$581.6M-19.1% | -$488.3M-4.4% | -$467.8M-21.3% | -$385.66M-5.3% | ||
| $19.06M-2.1% | $19.48M+4.4% | $18.66M-1.6% | $18.97M-1.0% | $19.16M-0.5% | ||
| $68.61M-5.4% | $72.5M-5.1% | $76.37M-6.1% | $81.31M-6.9% | $87.37M+0.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $6.27M+123% | ||
| -$3.72M-11.6% | -$3.34M-1,084% | $339K-38.5% | $551K+129% | -$1.89M+65.5% | ||
| —— | —— | —— | —— | —— | ||
| $16.98M-27.8% | $23.53M-22.5% | $30.37M+12.0% | $27.13M-3.0% | $27.98M-27.5% | ||
| —— | —— | -$3.19M-10.3% | -$2.89M-27.4% | -$2.27M-16.4% | ||
| -$399.96M-15.9% | -$345.01M-14.1% | -$302.49M+6.9% | -$324.77M-6.0% | -$306.47M-115% | ||
| $1.21M+32.6% | $914K+40.4% | $651K-18.2% | $796K-42.6% | $1.39M-27.1% | ||
| —— | $702K+33.3% | $526.5K+50.0% | $351K+100% | $175.5K— | ||
| —— | —— | —— | $20M-3.3% | $20.68M-10.8% | ||
| —— | —— | —— | —— | —— | ||
| $388.87M-2.3% | $398.11M+32.0% | $301.58M+923% | $29.48M0.0% | $29.48M-90.2% | ||
| —— | —— | —— | —— | —— | ||
| $1.01B+136% | $426.03M+30.5% | $326.49M+729% | $39.36M+6.1% | $37.1M-88.8% | ||
| —— | —— | —— | $109K+276% | $29K+226% | ||
| $184.61M+274% | $49.3M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$5.58M-7.1% | -$5.21M-6.5% | -$4.89M+1.2% | -$4.95M-7.9% | -$4.59M-4.2% | ||
| -$3.72M-11.6% | -$3.34M-1,084% | $339K-38.5% | $551K+129% | -$1.89M+65.5% | ||
| $16.98M-27.8% | $23.53M-22.5% | $30.37M+12.0% | $27.13M-3.0% | $27.98M-27.5% | ||
| —— | —— | —— | $20M-3.3% | $20.68M-10.8% | ||
| —— | $702K+33.3% | $526.5K+50.0% | $351K+100% | $175.5K— | ||
| —— | —— | —— | —— | —— | ||
| $32.02M+14.6% | $27.94M+12.1% | $24.93M+152% | $9.91M+21.2% | $8.17M-73.9% | ||
| —— | —— | —— | $109K+276% | $29K+226% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$401.18M-16.0% | -$345.93M-14.1% | -$303.14M+6.9% | -$325.57M-5.8% | -$307.86M-113% | ||
| -$401.18M-16.0% | -$345.93M-14.1% | -$303.14M+6.9% | -$325.57M-5.8% | -$307.86M-113% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CRISPR Therapeutics generate?
- CRISPR Therapeutics (CRSP) generated -$400.0M in operating cash flow over the trailing twelve months.
- What is CRISPR Therapeutics's free cash flow?
- After $1.2M of capital expenditures, CRISPR Therapeutics's free cash flow was -$401.2M over the trailing twelve months, down 30.3% year over year.
- Where does CRISPR Therapeutics's cash flow data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
